MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
The revised SPL outlook includes approximately $4 million from milestones and approximately $2 million from commercial royalties.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MaxCyte (MXCT) raised its full-year 2026 revenue outlook to approximately $34 million and reported preliminary third-quarter core business growth.
Core revenue was approximately $8.1 million, up 26% from the third quarter of 2025. Strategic Platform License (SPL) Program-related revenue exceeded $1.0 million, including $1.0 million in milestone revenue. Results are preliminary, unaudited and subject to change.
MaxCyte expects annual core revenue of approximately $28 million, versus $25 million to $27 million previously, and SPL revenue of approximately $6 million, versus approximately $5 million. Prior total guidance was $30 million to $32 million. The company attributed third-quarter outperformance to a large customer's instrument purchases moving forward from the fourth quarter. Full results, including royalty revenue, are scheduled for November 10, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.2026 revenue guidance rises to approximately $34 million from $30 million to $32 million.
- Moderate pointThird-quarter core revenue of approximately $8.1 million increased 26% versus the third quarter of 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.Core revenue guidance rises to approximately $28 million from $25 million to $27 million.
- Minor point. Forward-looking: it has not happened yet and may not happen.SPL guidance rises to approximately $6 million from approximately $5 million, including approximately $4 million milestones and $2 million royalties.
- Minor pointThird-quarter SPL revenue exceeded $1.0 million, including $1.0 million in milestone revenue.
2 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Updated core guidance reflects company-expected approximately 15% year-over-year growth in the second half of 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.SPL partnerships support two pivotal trials with potential approval as early as 2027, the company said.
Negative
- Minor pointThird-quarter results are preliminary and unaudited, subject to change during closing and review.
- Minor pointThird-quarter outperformance reflected accelerated large-customer instrument purchases originally anticipated in the fourth quarter, the company said.
News Explained
The company’s approximately
Details
Market move: MXCT +18.22% vs previous close. 2026 revenue guidance update
On Oct 14, the day this news came out, the latest delayed price for MXCT is 18.22% above the previous close. Argus tracked a peak move of +16.5% during the session. Our momentum scanner has recorded 24 alerts for this stock so far that day. The latest delayed price is $1.14. Relative volume is above average at 1.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Core business revenue
- Approximately $8.1 million; +26%
- Preliminary Q3 2026 revenue; growth compared with Q3 2025
- SPL Program-related revenue
- More than $1.0 million
- Q3 2026; includes $1.0 million in milestone revenue
- Full-year revenue guidance
- Approximately $34 million
- 2026 guidance, raised from $30 million to $32 million
- Core business revenue guidance
- Approximately $28 million
- 2026 guidance, raised from $25 million to $27 million
- SPL Program-related revenue guidance
- Approximately $6 million
- 2026 guidance, raised from approximately $5 million
- SPL guidance components
- Approximately $4 million in milestone payments; approximately $2 million in commercial royalties
- Components of 2026 SPL Program-related revenue guidance
Historical Context
-
Q2 reiterated the $30–32 million 2026 revenue guidance range that this update raised.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026
ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance.
Preliminary Third Quarter Revenue
- Core business revenue of approximately
$8.1 million in the third quarter of 2026, an increase of26% compared to the third quarter of 2025. - Strategic Platform License (SPL) Program-related revenue of more than
$1.0 million , including milestone revenue of$1.0 million received in the third quarter of 2026. MaxCyte will report royalty revenue with its full financial results on November 10, 2026.
MaxCyte’s third quarter results are preliminary, unaudited and subject to change in connection with the completion of MaxCyte’s quarterly closing process and review procedures. As a result, these preliminary results may differ from the actual results that will be reflected in MaxCyte’s consolidated financial statements for the quarter ended September 30, 2026.
Full Year 2026 Guidance
MaxCyte raises 2026 revenue guidance for core business revenue and SPL Program-related revenue:
- Full year revenue expected to be approximately
$34 million , compared to prior guidance of$30 million to$32 million , consisting of:- Core business revenue of approximately
$28 million , compared to prior guidance of$25 million to$27 million . - SPL Program-related revenue of approximately
$6 million for the year, compared to prior guidance of approximately$5 million ; SPL Program-related revenue guidance includes both revenue of approximately$4 million from milestone payments and approximately$2 million from commercial royalties.
- Core business revenue of approximately
“Preliminary third quarter and total second half revenue is ahead of our expectations, and we updated our core business revenue guidance to reflect approximately
Third Quarter Webcast and Conference Call Details
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure™ gene editing risk assessment services enable high-performance cell engineering and rigorous evaluation of editing outcomes, supporting confidence in therapeutic development. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine.
Learn more at maxcyte.com and follow us on LinkedIn and Bluesky.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements about us and our industry involve substantial known and unknown risks, uncertainties, and assumptions, including those described in Item 1A under the heading "Risk Factors" and elsewhere in our report on Form 10-K, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, customer expectations and objectives of management for future operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements about possible or future results of operations or financial position. In some cases, you can identify forward-looking statements because they contain words such as "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "seek," "predict," "future," "project," "potential," "continue," "contemplate," "target," the negative of these words and similar words or expressions. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. The forward-looking statements contained in this press release, include, without limitation, our full year 2026 revenue, our expectations regarding core business revenue growth in the second half of 2026, statements concerning the following: our expected future growth and success of our business model; the size and growth potential of the markets for our products, and our ability to serve those markets, increase our market share, and achieve and maintain industry leadership; our ability to expand our customer base and enter into additional SPL partnerships; expectations regarding customer-level activities (including the expected advancement of our SPL partners' clinical programs, including Phase 3 trial initiations); the timing and amount of any share repurchases under our share repurchase program; our financial performance and capital requirements; the adequacy of our cash resources and availability of financing on commercially reasonable terms; our expectations regarding general market and economic conditions that may impact investor confidence in the biopharmaceutical industry and affect the amount of capital such investors provide to our current and potential partners; and our use of available capital resources.
These and other risks and uncertainties are described in greater detail in Item 1A , entitled "Risk Factors," in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time. These documents are available through the Investor Menu, Financials section, under "SEC Filings" on the Investors page of our website at http://investors.maxcyte.com. Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
MaxCyte Contacts:
Investor Relations
Gilmartin Group
Erik Abdow
ir@maxcyte.com
Media Contact
Oak Street Communications
Kristen White
kristen@oakstreetcommunications.com
415.608.6060
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is MaxCyte's updated 2026 revenue guidance?
MaxCyte expects full-year 2026 revenue of approximately $34 million, up from $30 million to $32 million. The outlook includes approximately $28 million in core business revenue and approximately $6 million in SPL Program-related revenue.
How much preliminary third-quarter 2026 revenue did MaxCyte report?
MaxCyte reported preliminary core business revenue of approximately $8.1 million, up 26% year over year, and SPL Program-related revenue of more than $1.0 million. The figures are unaudited and subject to change; royalty revenue will be reported with full results on November 10, 2026.
What milestone and royalty revenue does MaxCyte expect in its 2026 SPL outlook?
MaxCyte's 2026 SPL outlook includes approximately $4 million from milestone payments and approximately $2 million from commercial royalties. These amounts form its approximately $6 million full-year SPL Program-related revenue guidance.